Background-Left atrial (LA) structure and function are altered in most heart failure (HF) patients, but there may be fundamental differences in LA properties between HF with preserved (HFpEF) and reduced ejection fraction (HFrEF).
T he left atrium modulates left ventricular (LV) filling by acting as an elastic reservoir, passive conduit, and active booster. 1 Left atrial (LA) dysfunction and remodeling are commonly observed in patients with heart failure (HF). Growing evidence suggests that LA dysfunction is an active contributor to symptoms [2] [3] [4] [5] and to disease progression. 3, 6, 7 HF-related LA remodeling is poorly understood, and it is not known whether there are fundamental differences between HF patients with preserved (HFpEF) or reduced LV ejection fraction (HFrEF), though prior studies suggest greater adverse effects from loss of LA function in HFpEF compared with HFrEF. 8 
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The LA also serves as a watershed between the LV and the pulmonary circulation, buffering pressure and flow oscillations because of the cyclic nature of cardiac work. Impaired LA function can thus impose greater hemodynamic stress on the pulmonary vasculature, promoting remodeling and worsening pulmonary hypertension (PH), as observed in patients with mitral stenosis. 9, 10 Increased pulmonary vascular resistance and stiffness may elevate right ventricular (RV) afterload, 11 driving further the progression to RV failure. [12] [13] [14] [15] We hypothesized that LA function is abnormal in patients with HF, that LA remodeling differs between patients with HFrEF and similarly advanced HFpEF, and that LA dysfunction is associated with abnormal pulmonary vascular properties and RV dysfunction. To test this hypothesis, we examined HFrEF and HFpEF patients undergoing invasive and noninvasive hemodynamic assessment and compared them with HF-free controls to address the differences in LA structure, function, and to assess the effect of LA dysfunction on the pulmonary vasculature, right heart, and clinical outcomes.
Methods

Study Subjects
Consecutive patients referred to Mayo Clinic (Rochester, MN) undergoing right heart catheterization and echocardiography within a 48-hour window with sufficient raw data available for detailed assessment (pressure waveforms and echocardiographic images) were identified. HF was defined by cardiologist-adjudicated HF diagnosis (Framingham criteria) of >6 month duration and elevated pulmonary artery (PA) wedge pressure (PAWP ≥15 mm Hg at rest or ≥25 mm Hg at exercise). HFpEF and HFrEF were defined by LV EF ≥50% and <50%, respectively. Patients with congenital heart disease, endocarditis, carcinoid, amyloid, constrictive, restrictive or hypertrophic cardiomyopathy, intracardiac shunt (other than patent foramen ovale), high output HF, non-Group II PH, mitral valve replacement, organic valvular disease, acute coronary syndrome, or hemodynamic instability were excluded.
Subjects with no cardiovascular disease other than Stage 1 arterial hypertension were identified from patients undergoing preoperative evaluation, percutaneous closure of patent foramen ovale, or evaluation for dyspnea with no identifiable cardiovascular cause. Past medical history, medication use, and contemporaneous laboratory data (±1 week) were abstracted from the medical records. Significant coronary artery disease was defined as one or more ≥70% epicardial artery stenosis or previous revascularization (angiography available in 28% controls, 82% of HFpEF, and 100% of HFrEF). For time-to-event analysis, patient vital status was determined using outpatient records and the Social Security Death Index. Patients who underwent heart transplantation or ventricular assist device insertion were censored as alive at the day of surgery. The study was approved by Mayo Clinic institutional review board.
Assessment of Hemodynamics and Cardiac Function
Right heart catheterization was performed in the supine position via the jugular or femoral vein using a balloon-tipped catheter as previously described. 16 Right atrial (RA), RV, PA pressures, and PAWP were determined at end-expiration. All atrial waveforms were visually inspected by an experienced cardiologist blinded to clinical data and group allocation to determine minimal, maximal, v wave, and a wave pressures within one cardiac cycle ( Figure 1 ). Transpulmonary gradient was calculated as PA mean-PAWP pressure, pulmonary vascular resistance (PVR) was calculated as transpulmonary gradient/cardiac output, and PA compliance was calculated as stroke volume/PA pulse pressure. Two-dimensional and Doppler echocardiography was performed according to American Society of Echocardiography guidelines 17 by experienced sonographers and cardiologists. Cardiac output was derived from heart rate, LV outflow tract diameter, and pulsed Doppler time-velocity integral. LV mass was calculated using the Devereux formula. 5 Diastolic function was assessed by measurements of transmitral flow velocities (E and A), E-wave deceleration, mitral annulus tissue velocities in early and late diastole (E′ and A′, average of septal and lateral) using pulsed Doppler echocardiography. Diastolic dysfunction was graded as described previously. 18 Valve regurgitations were quantified according established guidelines. 19 LV EF was determined by the modified Quinones formula that corrects for endocardial echo dropouts and image foreshortening. 20 Apical 4-chamber views were reviewed offline to measure maximal LA volume (frame before mitral valve opening), diastasis LA volume (frame before LA contraction), and minimal LA volume using arealength method. Global and reservoir LA function was characterized by total LA EF, 7 LA conduit function was characterized by passive LA EF, and contractile function was characterized by active LA EF (Figure 1 ). 21 Atrial function was also assessed by LA function index, which normalizes function to stroke volume and is rhythm-independent. 3 Operant LA diastolic stiffness was approximated as the slope of linear regression of minimal and maximal LA pressure-volume coordinates (Figure 1 ). 22, 23 Meridional LA wall stress was calculated from maximal to minimal LA volume and pressure using established formulas, 24 assuming atrial wall thickness of 0.2 cm. 25 RV function was assessed as previously 26 by tracing the RV endocardium in the apical 4-chamber view in systole and diastole to obtain fractional area change (RV FAC %). The right atrial endocardium was tracked in the frame before tricuspid valve opening to obtain maximal RA volume using the area-length method. 27
Statistical Methods
Data were analyzed using JMP10 (SAS Institute Inc., Cary, NC). Distributions of continuous variables were visually assessed for normality, and summary data in the tables are reported as mean (standard deviation) or median (25th-75th interquartile range). Betweengroup differences were compared by ANOVA with Tukey post hoc test, 2×2 ANOVA, or χ 2 tests as appropriate. Univariate and multivariate Cox proportional hazard model were used to examine the effect of LA function on outcome. To allow comparisons, parameters describing LA function were z-standardized in individual subgroups. Graphs represent mean±SE.
Results
Clinical characteristics of controls (n=40) and both HF groups (HFpEF, n=101; HFrEF, n=97) are summarized in Table 1 . Both HF groups were highly symptomatic (74% New York Heart Association [NYHA] III-IV) with ≥80% of chronic diuretic use. Similar to prior studies, 28 HFpEF patients were slightly older, more likely to be women, more obese, and more often in atrial fibrillation (AF). Prevalence of coronary artery disease, diabetes mellitus, and renal dysfunction was similar. HFpEF patients had higher systemic blood pressure, cardiac output, LV EF, and transmitral flow velocities, but smaller LV size, LV mass, and mitral regurgitation grade compared with HFrEF ( Table 2) .
LA Structure and Function in HFpEF Versus HFrEF
Compared with controls, patients with HFrEF and HFpEF displayed LA dilatation, coupled with reduced LA active contractile, reservoir, and conduit functions (Table 2 and Figure 2 ). Patients with HFpEF displayed greater LA stiffness, whereas (n=130) . B, The effect of mitral regurgitation grade on peak LA pressure (LA v-wave, left) and min-max LA wall stress change (right) in controls, heart failure with reduced ejection fraction (HFrEF), and heart failure with preserved ejection fraction (HFpEF). Lines represent results of linear regression with 95% confidence intervals and correlation coefficients. Thus, LA performance is reduced because of impairment of the Frank-Starling mechanism in both HF groups, whereas the presence of mitral regurgitation is associated with higher wall stress variations and greater v-wave height in HFpEF.
HFrEF patients displayed more eccentric LA remodeling (Figure 2 ). At similar mean LA pressure (Table 2) , patients with HFrEF had larger LA volumes and more depressed LA systolic function than HFpEF. In contrast, patients with HFpEF were characterized by higher maximal LA pressure (v-wave), lower minimal LA pressures, and increased LA stiffness (Table 2) , with a steeper, leftward-shifted LA diastolic pressure-volume relationship (Figure 2 ). Differences in LA volume and stiffness between HFpEF and HFrEF persisted after adjustments to sex, age, body size and mass, AF or mitral regurgitation grade (adjusted P values <0.02).
Left atrial pulsatility (LA max-min pressure) and wall stress variation was higher in HFpEF compared with HFrEF ( Table 2) . LA function curves (preload-stroke volume plots) were shallower in both HFpEF and HFrEF compared with controls, indicating LA contractile dysfunction regardless of LA geometry (Figure 3 ). LA functional index and A′ mitral annular velocities were also more reduced in HFrEF than in HFpEF or controls ( Table 2) .
The presence of AF was associated with more severe LA dilatation, lower total LA EF, and higher LA stiffness, particularly in HFpEF group (Figure in the Data Supplement). Both atrial rhythm and HF phenotype affected LA structure and function as shown by factorial analysis. LA volume and stiffness increased, whereas total LA EF decreased with worsening NYHA class (Figure 4 ). Mitral regurgitation had greater effects in HFpEF than HFrEF, with higher peak LA pressure (LA v-wave) and greater LA wall stress variation with increasing mitral regurgitation in HFpEF compared with HFrEF ( Figure 3 ).
Left Atrium and Pulmonary Artery-Right Heart Function
Pulmonary hypertension was common in HF patients (82% HFpEF, 79% HFpEF) because of combination of elevated PAWP and increased transpulmonary gradient (Table 3) . Mean PA pressure, transpulmonary gradient, PVR, and pulmonary arterial compliance (PAC) were similarly increased in both HF groups (Table 3) , whereas PA pulse pressure was higher in HFpEF. Global left atrial function (total LA EF) correlated inversely with PVR and positively with PAC in both HF groups, but not in controls, and the slope the relationship was similar between HFpEF and HFrEF ( Figure 5 ). Similarly, LA stiffness correlated with PAC in HFpEF and HFrEF (r=−0.35 and r=−0.41; both P<0.001), but only weakly with PVR in HFpEF (r=0.23; P=0.03) and was unrelated to PVR in HFrEF (r=0.12, P=0.3). LA volume was unrelated to PVR or PAC in both HF phenotypes. Both HFpEF and HFrEF patients displayed RV dilation, but RV systolic function was somewhat lower in HFrEF. Global LA function (total LA EF) positively correlated with RV function in HFpEF and HFrEF with similar slope ( Figure 5 ).
Effect of LA Dysfunction on Prognosis
Over a median follow-up duration of 350 days (IQR, 82-870), there were 59 deaths (HFpEF=28 and HFrEF=31). Outcome was ascertained in 100% of HF subjects. In univariate Cox analysis, reduced global and active LA function (total LA EF and active LA EF), increased LA volume, and AF were all associated with an increased risk of death in HFpEF, but not in HFrEF ( Figure 6) . In multivariate Cox model that included age and sex, known predictors of mortality in HFpEF, 29 either total LA EF or active LA EF remained a significant predictor of death in HFpEF (P=0.03 and P=0.05), whereas LAVI was no longer predictive (P=0.16). NT-pro-BNP levels were not predictive of mortality in either HF group.
Discussion
This study examined LA structure and function in HF by combining invasive pressure and noninvasive volume data, contrasting LA parameters in the 2 HF phenotypes. Compared with controls, both HF types displayed abnormal LA size and function. The HFrEF group was characterized by greater eccentric LA remodeling, whereas the HFpEF group was characterized by increased LA stiffening and greater LA pressure pulsatility, indicating that higher wall stress variations may contribute to greater burden of AF observed in HFpEF. In both groups, LA function was associated with pulmonary vascular disease and right HF. Although global LA function was less impaired in HFpEF than HFrEF, LA dysfunction was more strongly associated with mortality in this cohort, suggesting greater vulnerability to loss of LA function in HFpEF. These data highlight the importance of atrial dysfunction in HF and suggest that strategies to optimize LA function or to prevent its deterioration may mitigate progression of pulmonary vascular and right heart dysfunction to improve outcomes in HF patients and particularly in HFpEF.
Few studies have compared LA structure/function in HFpEF and HFrEF, and none have reported associations between LA function and outcome. 6, 30, 31 In an echocardiographic study, Triposkiadis et al compared LA remodeling in HFpEF and HFrEF and found more eccentric LA remodeling in HFrEF group, similarly to the current data. 31 In a smaller sample, Kurt et al reported that HFpEF patients had LA enlargement, reduced LA function, and increased LA stiffness compared with controls, but in contrast to the current study, LA stiffness was not as high in HFpEF as in HFrEF. 30 However, the Kurt study measured only mean PAWP rather than peak and minimal LA pressures, and the authors estimated LA stiffness simply as the ratio of mean PAWP to LA systolic strain, in contrast to the more robust methods used in the current study incorporating maximal and minimal LA pressure-volume coordinates. The current observation of smaller and stiffer left atrium in HFpEF as compared with HFrEF is congruent with known structure-function differences noted at the left ventricular level, supporting the notions that HFpEF and HFrEF represent 2 distinct pathophysiological entities 32 and that the systemic processes favoring stiffening in all cardiac chambers, such as microvascular inflammation or impaired nitric oxide availability, may contribute to the pathophysiology of HFpEF. 33 Two overarching mechanisms are thought to drive the development of atrial dysfunction in HF-chronic changes in loading (increased atrial preload and afterload) and the loss of normal atrial electric activity. 10, 34 Experimental and limited human studies 22, 35 have illustrated that with increased preload, LA contractility initially rises 22, 35, 36 but later declines, coinciding with adverse changes in remodeling, apoptosis, myosin isoform expression, collagen matrix turnover, and reduced intrinsic contractility. [36] [37] [38] As shown in the current data at the macro level, this translates to an increase in atrial wall stiffness reflected by the steeper and upward-shifted pressure-volume relationship, predominantly in HFpEF, and by a shift to the larger LA volumes, predominantly in HFrEF. Despite the difference in LA volumes, we noted that LA function curves (preload-stroke volume relations) were similarly flattened in HFrEF and HFpEF, indicating presence of intrinsic LA dysfunction. In HFpEF, the increase of LA stroke volume by preload recruitment (Frank-Starling mechanism) can be blunted by increased LA stiffness, as recently suggested. 39 As shown in the current study, loss of normal atrial electric activity in HF patients with AF is associated with more pronounced LA dilatation, systolic dysfunction, and passive stiffening (Figure in the Data Supplement). However, HF patients in sinus rhythm also demonstrated LA systolic impairment (active LA EF reduced by 37% in HFpEF and 54% in HFrEF), confirming that atrial mechanical dysfunction in HF is not restricted to patients with AF. [40] [41] [42] At similar mean LA pressures, HFpEF patients demonstrated larger LA pressure pulsatility 43 and greater LA wall stress variation. We speculate that this may contribute to the higher prevalence of AF noted in HFpEF compared with HFrEF, despite smaller LA volumes, similar LA pressures, and similar HF severity and mortality risk. 44 The differences in LA structure-function also seem to influence how the LA copes with mitral regurgitation. With increasing regurgitation, LA pressure and wall stress increases much more steeply in HFpEF than in HFrEF, which may promote stretch-mediated atrial ectopy that plays a role in initiation of AF. 34 Although LA function was less impaired in HFpEF than in HFrEF, its association with outcome was more pronounced, congruent with previous reports regarding the differential effect of AF on outcomes in HFpEF or HFrEF. 8 The current data provide insight into the mechanisms by which this HF phenotype-specific difference may originate.
Previous studies have suggested a potential association between atrial dysfunction and pulmonary hemodynamics, but these noninvasive studies were not able to discriminate between the effect of intrinsic LA properties from passive LA pressure elevation because of volume overload. 9, 30, 45 We observed that impaired LA global systolic function (quantified by total LA EF) 7 correlated with increased PVR and reduced PAC measured directly by cardiac catheterization. Impaired diastolic LA function (LA stiffness) was associated with reduced PAC, a measure of oscillatory PA load. The relations between LA functional properties and pulmonary vasculature were similar between HFpEF and HFrEF. The current data strongly implicate that LA dysfunction belongs among the mediators of pulmonary vascular disease in HF. 11 By having effect in PA hemodynamics, LA dysfunction can also indirectly influence RV function and contribute to progression toward biventricular failure with poor prognosis. 26, 46 These data suggest that maintenance or restoration of normal LA function may help to protect the pulmonary vasculature, and in doing so, to prevent deterioration of the right heart. Further studies are required to assess whether this approach is beneficial. Conversely, these data also indicate that LA interventions that might increase stiffness or impair systolic function might have unintended adverse consequences on the pulmonary vasculature. Left atrial wall scarring and volume reductions after repeated radiofrequency AF ablations have recently been associated with development of PH, 47 and removal of LA appendage, the most contractile and compliant part of the left atrium, increases atrial stiffness and reduces atrial performance. 37 As LA interventions, such as device closure and ablation, become more widely used in HF patients, the potential for deleterious effects on pulmonary vascular-right heart function should be considered and evaluated in future trials.
Limitations
This study is retrospective, observational, and is influenced by referral bias. All subjects underwent cardiac catheterization, so this sample is generally limited to patients with more advanced HF and may not be applicable to the entire HF population. The use of PAWP for inclusion into HF group assured that the patients studied truly had HF, but because patients with less advanced HF may have normal PAWP at rest, these results may not apply to HF patients with earlier stage disease. The primary cause of ventricular dysfunction in HF patients could not be assessed in this retrospective study. The control group was drawn from consecutive patients referred for invasive assessment, so by virtue of being referred for cardiac catheterization, this is not representative of completely healthy comparator group. However, this invasive study would not be feasible in healthy volunteers. Hemodynamic and echocardiographic data were not acquired simultaneously, but both occurred within a 48 hour time frame. The relations between HF phenotype and atrial characteristics were studied crosssectionally, so all inferences about causality are hypothesisgenerating. Despite age-adjusted comparisons, differences in age between groups may confound the conclusions. Data on quality of life were not systematically recorded, and all measures were performed at rest and in the supine position, so we were unable to address the relation of our findings to exertional symptoms or quality of life.
LA pressures were not measured directly, but assessed by PAWP, which is dampened compared with directly measured LA pressures, leading to systematic underestimation of diastolic LA stiffness and pulsatility, though this underestimation was uniform between HF groups and controls. The number of enrolled subjects and deaths was moderate, which both prevented multivariable analysis. Thus, further work is needed to confirm the univariate relationships we observed between LA size/function and outcomes, which could be potentially cofounded by other intermediary factors. However, follow-up was complete in 100% of patients, enhancing confidence in our results.
In conclusion, the current data provide insight into pathophysiology of LA dysfunction and PH in HF. The LA remodeling in HFpEF and HFrEF differs, with more dilation and systolic dysfunction in HFrEF and with increased stiffness, pulsatility, and predilection for AF in HFpEF. Restoration of LA mechanical function may have favorable effects on pulmonary vasculature and right heart, whereas processes and interventions that reduce atrial contractility or adversely affect LA compliance may promote and exacerbate PH, leading to right heart dysfunction and increased risk of adverse outcomes, especially in patients with HFpEF. 
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